Business Standard

AstraZeneca agrees to pay Japan's Daiichi $6 bn for new cancer drug

The UK drugmaker will pay Japan's Daiichi $1 billion upfront to jointly develop and bring to market a cancer therapy in early clinical tests called DS-1062, the companies said

Petition will come up for hearing on Thursday
Premium

Besides the cancer deals, Daiichi is in talks to make Astra’s Covid-19 vaccine in Japan

Bloomberg
AstraZeneca Plc agreed to pay as much as $6 billion to buy into Daiichi Sankyo Co.’s promising medicine for lung and breast cancer, the drugmakers’ second potential blockbuster oncology deal in two years.

The UK drugmaker will pay Japan’s Daiichi $1 billion upfront to jointly develop and bring to market a cancer therapy in early clinical tests called DS-1062, the companies said Monday. As much as $5 billion in additional payments could follow, subject to regulatory and sales milestones.

AstraZeneca is forging ahead to become a global oncology powerhouse, even as it works on a vaccine for the coronavirus pandemic. Last year,

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 27 2020 | 11:47 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com